Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease mediated by a complex interaction between the autoreactive lymphocytes and the effector myeloid cells within the central nervous system (CNS). In a murine model of MS, experimental autoimmune encephalomyelitis (EAE), Ly6Chi monocytes migrate into the CNS and further differentiate into antigen-presenting cells (APCs) during disease progression. Currently, there is no information about gene signatures that can distinguish between monocytes and the monocyte-derived APCs. We developed a surface marker-based strategy to distinguish between these two cell types during the stage of EAE when the clinical symptoms were most severe, and performed transcriptome analysis to compare their gene expression. We report here that the inflammatory CNS environment substantially alters gene expression of monocytes, compared to the monocyte differentiation process within CNS. Monocytes in the CNS express genes that encode proinflammatory cytokines and chemokines, and their expression is mostly maintained when the cells differentiate. Moreover, monocyte-derived APCs express surface markers associated with both dendritic cells and macrophages, and have a significant up-regulation of genes that are critical for antigen presentation. Furthermore, we found that Ccl17, Ccl22, and Ccr7 are expressed in monocyte-derived APCs but not the Ly6Chi monocytes. These findings may shed light on identifying molecular signals that control monocyte differentiation and functions during EAE.

Highlights

  • Multiple sclerosis (MS) is one of the most common neurological disorders among young adults

  • We propose that the expression of Ccl17, Ccl22, and Ccr7 may serve as marker genes to distinguish between monocytes and the monocyte-derived antigen-presenting cells (APCs) in the central nervous system (CNS)

  • During inflammation in the CNS, monocytes and monocytederived APCs cannot be morphologically distinguished from microglia, non-parenchymal CNS-associated macrophages, and conventional dendritic cells

Read more

Summary

Introduction

Multiple sclerosis (MS) is one of the most common neurological disorders among young adults. Current disease modifying agents (DMAs) for MS treatments reduce the rate of relapses, but these treatments do not effectively prevent disease progression [1, 2]. It has been demonstrated that mononuclear myeloid cells can directly mediate inflammation, demyelination, and axonal damage [4, 5]. These cells are an ideal target for novel MS therapies

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call